Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Journal of Pharmaceutical and Biomedical Analysis
|
August 20, 2013
Drug interference in immunogenicity assays depends on valency
Theo Rispens, Margreet H Hart, Pleuni Ooijevaar-de Heer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 21, 2012
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
Anke Vennegoor, Theo Rispens, Eva Mm Strijbis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 16, 2015
MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS
Mike P Wattjes, Martijn T Wijburg, Anke Vennegoor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
August 18, 2016
MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance
Martijn T Wijburg, Birgit I Witte, Anke Vennegoor, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 14, 2015
Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients
Mike P Wattjes, Martijn T Wijburg, Anke Vennegoor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 11, 2014
MRI pattern in asymptomatic natalizumab-associated PML
Mike P Wattjes, Anke Vennegoor, Martijn D Steenwijk, et al.
Journal of Autoimmunity
|
December 5, 2009
T lymphocytes impair P-glycoprotein function during neuroinflammation
Gijs Kooij, Jack van Horssen, Elizabeth C M de Lange, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 4, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients
Alyssa A Toorop, Mark Hj Wessels, Lynn Boonkamp, et al.
JAMA Neurology
|
December 9, 2024
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial
Eline M E Coerver, Wing Hee Fung, Janet de Beukelaar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
Liza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Journal of Pharmaceutical and Biomedical Analysis
|
August 20, 2013
Drug interference in immunogenicity assays depends on valency
Theo Rispens, Margreet H Hart, Pleuni Ooijevaar-de Heer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 21, 2012
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
Anke Vennegoor, Theo Rispens, Eva Mm Strijbis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 16, 2015
MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS
Mike P Wattjes, Martijn T Wijburg, Anke Vennegoor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
August 18, 2016
MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance
Martijn T Wijburg, Birgit I Witte, Anke Vennegoor, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 14, 2015
Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients
Mike P Wattjes, Martijn T Wijburg, Anke Vennegoor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 11, 2014
MRI pattern in asymptomatic natalizumab-associated PML
Mike P Wattjes, Anke Vennegoor, Martijn D Steenwijk, et al.
Journal of Autoimmunity
|
December 5, 2009
T lymphocytes impair P-glycoprotein function during neuroinflammation
Gijs Kooij, Jack van Horssen, Elizabeth C M de Lange, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 4, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients
Alyssa A Toorop, Mark Hj Wessels, Lynn Boonkamp, et al.
JAMA Neurology
|
December 9, 2024
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial
Eline M E Coerver, Wing Hee Fung, Janet de Beukelaar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
Liza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
Page
of 3